Abstract
The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
CNS & Neurological Disorders - Drug Targets
Title:From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications
Volume: 11 Issue: 6
Author(s): Ana M. Sebastiao, Filipa F. Ribeiro and Joaquim A. Ribeiro
Affiliation:
Keywords: Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, γ-aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, Adenosine receptors, brain-derived neurotrophic factor, cannabinoids, aminobutyric acid, glutamate, hippocampus, neuroprotection, vasoactive intestinal peptide, ACh, AMPA
Abstract: The role of A1 and A3 receptors is discussed based on data almost exclusively obtained in the hippocampus. This brain area, where A1 receptor expression predominates, has been a matter of intensive research in the adenosine field. Interestingly, in the last decade, the relevance of the much less expressed adenosine receptor in the hippocampus, the A2A receptor, has been put forward. These two high affinity receptors operate as effective regulators of a number of neurotransmitters and/or neuromodulators, through modulation of their release, action, or even inactivation. Therefore, A1 and A2A receptors constitute a must in the discussion about adenosine receptors in the hippocampus, and consequently, about the potential implications of their pharmacological manipulation and drug targeting.
Export Options
About this article
Cite this article as:
M. Sebastiao Ana, F. Ribeiro Filipa and A. Ribeiro Joaquim, From A1 to A3 en passant Through A2A Receptors in the Hippocampus: Pharmacological Implications, CNS & Neurological Disorders - Drug Targets 2012; 11 (6) . https://dx.doi.org/10.2174/187152712803581074
DOI https://dx.doi.org/10.2174/187152712803581074 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Valproic Acid in the Complex Therapy of Malignant Tumors
Current Drug Targets Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Routine Collection of Patient-Reported Outcomes in an HIV Clinic Setting:The First 100 Patients
Current HIV Research Ghrelin as a Neuroprotective and Palliative Agent in Alzheimer's and Parkinson's Disease
Current Pharmaceutical Design HHT: A Rare Disease with A Broad Spectrum of Clinical Aspects
Current Pharmaceutical Design Modulation of the Basal Ganglia by Metabotropic Glutamate Receptors: Potential for Novel Therapeutics
Current Drug Targets - CNS & Neurological Disorders Editorial [Hot Topic: Membrane Channels as Therapeutic Targets (Executive Editor: Jean-Claude Herve)]
Current Pharmaceutical Design Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
CNS & Neurological Disorders - Drug Targets Transglutaminase Inhibition as a Possible Therapeutical Approach to Protect Cells from Death in Neurodegenerative Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Targeting of Neuronal Kv7.2/3 Channels: A Focus on Chemotypes and Receptor Sites
Current Medicinal Chemistry β-Lactams as Neuroprotective Agents
Anti-Infective Agents in Medicinal Chemistry Synthesis and Structure-Activity Relationship on Anticonvulsant Aryl Semicarbazones
Medicinal Chemistry White Matter Damage Along the Uncinate Fasciculus Contributes to Cognitive Decline in AD and DLB
Current Alzheimer Research Somatostatin and Cognitive Function in Neurodegenerative Disorders
Mini-Reviews in Medicinal Chemistry Neurological Disorders of Purine and Pyrimidine Metabolism
Current Topics in Medicinal Chemistry Mitochondriotropic Cationic Vesicles A Strategy Towards Mitochondrial Gene Therapy
Current Pharmaceutical Biotechnology Regulation and Quantification of Cellular Mitochondrial Morphology and Content
Current Pharmaceutical Design The Therapeutic Role of Electroencephalography in Deep Brain Stimulation in Intractable Epilepsy: A Recent Perspective
Recent Patents and Topics on Imaging (Discontinued) Synthesis and Evaluation of Anticonvulsant Activities of Pyrazol yl Semicarbazones. Part II
Letters in Drug Design & Discovery Disrupted Structural Brain Network in AD and aMCI: A Finding of Long Fiber Degeneration
Current Alzheimer Research